Diabetes Mellitus-Pathophysiology-Assignment Solution, Exercises of Pathophysiology

This is solution to assignment which was given at University of Lucknow by Dr. Anurati Shah for Pathophysiology course. It includes: Diabetes, Mellitus, Type, Pharmacologic, Interventions, Treatment, Strategies, Oral, Hypoglycemics, Monitoring, Efficacy

Typology: Exercises

2011/2012

Uploaded on 07/23/2012

khushia
khushia 🇮🇳

4.1

(10)

110 documents

1 / 2

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
I. CASE DESCRIPTION
A 29 year old male who works at your clinic believes he has diabetes mellitus. His father and paternal
grandfather both developed this disease late in life. He has polyuria, polydypsia and polyphagia
accompanied by weakness, weight loss and blurry vision. You test his urine and find 3+ glycosuria; blood
glucose is 450 mg/dL. The patient does not want to take insulin and hopes that pills will be enough. On
the other hand, he has heard that oral hypoglycemics can be bad for you.
II. DIABETES MELLITUS TYPE II
1. is characterized by insulin resistance and relative insulin deficiency
2. is associated with both hereditary and environmental factors
Æ40-50% increase in risk for individual with affected first degree relatives
Æ significant association with obesity
3. if uncontrolled, may lead to such pathologies as diabetic retinopathy, autonomic neuropathy and
nephropathy
III. NON-PHARMACOLOGIC INTERVENTIONS
1. Diet changes: Low calorie diet can reduce fasting glucose and increase insulin sensitivity in five days
(hypothesized due to hepatic glycogenolysis).
a) not effective over long term (three years in the United Kingdom Prospective Diabetes Study)
2. Exercise: Besides weight loss, produces increased insulin sensitivity and delays onset of overt
diabetes.
IV. TREATMENT STRATEGIES WITH ORAL HYPOGLYCEMICS
[Diagram removed for copyright reasons.]
Inzucchi. (
2002) JAMA 287 (3): 360-372.
A. Monitoring efficacy
1. Blood glucose concentrations
a) measure mean blood glucose concentrations before meals and bedtime; mid
morning and mid afternoon
b) keep track of fluctuations over the day
c) monitor day-to-day variations in mean glucose level
2. HbA1c
a) average measurement indicates mean glucose level over the previous 6 to 8
weeks. Target is 7.0%
b) potential for false values: falsely high if RBC turnover is lower than normal
(eg., iron deficiency anemia) or low if turnover higher than normal (eg.,
hemolysis)
docsity.com
pf2

Partial preview of the text

Download Diabetes Mellitus-Pathophysiology-Assignment Solution and more Exercises Pathophysiology in PDF only on Docsity!

I. CASE DESCRIPTION

A 29 year old male who works at your clinic believes he has diabetes mellitus. His father and paternal

grandfather both developed this disease late in life. He has polyuria, polydypsia and polyphagia

accompanied by weakness, weight loss and blurry vision. You test his urine and find 3+ glycosuria; blood

glucose is 450 mg/dL. The patient does not want to take insulin and hopes that pills will be enough. On

the other hand, he has heard that oral hypoglycemics can be bad for you.

II. DIABETES MELLITUS TYPE II

1. is characterized by insulin resistance and relative insulin deficiency

2. is associated with both hereditary and environmental factors

Æ40-50% increase in risk for individual with affected first degree relatives

Æ significant association with obesity

3. if uncontrolled, may lead to such pathologies as diabetic retinopathy, autonomic neuropathy and

nephropathy

III. NON-PHARMACOLOGIC INTERVENTIONS

1. Diet changes: Low calorie diet can reduce fasting glucose and increase insulin sensitivity in five days

(hypothesized due to hepatic glycogenolysis).

a) not effective over long term (three years in the United Kingdom Prospective Diabetes Study)

2. Exercise: Besides weight loss, produces increased insulin sensitivity and delays onset of overt

diabetes.

IV. TREATMENT STRATEGIES WITH ORAL HYPOGLYCEMICS

[Diagram removed for copyright reasons.]

Inzucchi. (2002) JAMA 287 (3): 360-372.

A. Monitoring efficacy

1. Blood glucose concentrations

a) measure mean blood glucose concentrations before meals and bedtime; mid

morning and mid afternoon

b) keep track of fluctuations over the day

c) monitor day-to-day variations in mean glucose level

2. HbA1c

a) average measurement indicates mean glucose level over the previous 6 to 8

weeks. Target is 7.0%

b) potential for false values: falsely high if RBC turnover is lower than normal

(eg., iron deficiency anemia) or low if turnover higher than normal (eg.,

hemolysis)

docsity.com

B. Classifying oral hypoglycemics

Approach Class Cost: Fasting Lipid profile Side effects 30 days plasma HbA1c of tx glucose (%) (mg/dL) Improve Biguanides 50-70 1.5-2 Decrease TG, LDL Weight loss insulin action -metformin $70.43 Increase HDL GI events Lactic acidosis TZD’s 60-80 1.4-2.6 Weight gain -rosiglitazone $78.00 Increase HDL, LDL Fluid retention Lower Hb Increase Sulfonylureas 60-70 0.8-2 None Weight gain insulin -chlorpropamide $18.54 Hypoglycemia secretion -glipizide $10.

Meglitinides -ripaglinide $27.

65-75 0.5-2 None Weight gain Hypoglycemia Modulate α-glucosidase 25-30 0.7-1.0 none GI disturbances carbohydrate inhibitors absorption -acarbose $51.

http://www.endotext.org/diabetes/diabetes16/diabetes16.htm

Up-To-Date 2005

C. Pharmacokinetics

Class Onset of effect within Duration (hrs) Time to observe significant change in HbA1c Biguanides days More than 3-4 weeks 3 mo. TZD’s 12 weeks for max effect “ 6 mo. Sulfonylureas -chlorpropamide 6-8 hrs 24-

3 mo.

-glipizide (^) 1.5-2 hrs 14- Meglitinides 15-60 min. Max 24 3 mo. α-glucosidase inhibitors 4 3 mo. Cheng AYY t al. (2005) CMAJ. 172 (2): 213- Up-to-Date 2005.

D. Structuring therapy?

1. Monotherapy: determined by tolerable side effect profile and expense

2. Most combinations of two oral hypoglycemics equally effective:

a) using less than maximum doses, combination is more effective than monotherapy at reducing

HbA1c

b) certain combinations not recommended:

i) SU+ another inducer of insulin secretion (risk of hypoglycemia)

3. Including insulin: when target of 7.0% HbA1c not reached

a) Insulin + one oral hypoglycemic shown to be more effective than adding a third oral

hypoglycemic drug to regimen

b) Avoid certain combinations:

i) Any inducer of insulin secretion + preprandial insulin (risk of hypoglycemia)

ii) TZD + insulin (risk peripheral edema and heart failure)

V. INSULIN MONOTHERAPY

1. Side effects of weight gain and hypoglycemia may be more severe than combination therapy.

2. Necessary for patients with persistent hyperglycemia.

docsity.com